Our Pricing

Is Wegovy Better Than Mounjaro? Evidence-Based UK Comparison

Published on: June 03, 2026

Is Wegovy better than Mounjaro for weight loss? This is one of the most common questions we receive at Cured Pharmacy from patients seeking prescription weight management treatment. Both medications are GLP-1 receptor agonists licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related conditions, but they differ in active ingredient, mechanism of action, clinical trial outcomes, and tolerability profiles. As a UK-registered pharmacy with a specialist weight loss clinic, we've supported thousands of patients in choosing between semaglutide (Wegovy) and tirzepatide (Mounjaro) based on individual clinical suitability, treatment goals, and budget.

Is Wegovy Better Than Mounjaro: Clinical Trial Evidence

When comparing whether Wegovy is better than Mounjaro, clinical trial data provides the most robust evidence. The STEP trial programme evaluated semaglutide 2.4mg (Wegovy) and demonstrated an average weight loss of 14.9% of initial body weight over 68 weeks in the pivotal STEP 1 trial [1]. Participants lost an average of 15.3kg compared to 2.6kg with placebo, with 86.4% achieving at least 5% weight loss.

The SURPASS-2 head-to-head trial directly compared tirzepatide (Mounjaro) with semaglutide 1mg (Ozempic dose, not the higher Wegovy dose) and found tirzepatide delivered superior weight loss across all three dose strengths [2]. At the highest 15mg dose, tirzepatide produced average weight loss of 11.2kg versus 5.7kg with semaglutide 1mg over 40 weeks. Importantly, this compared Mounjaro against a lower semaglutide dose than Wegovy provides.

The SURMOUNT-1 trial assessed tirzepatide specifically for weight management in non-diabetic adults and reported average weight loss of 20.9% with the 15mg dose over 72 weeks — the highest efficacy recorded in any obesity medication trial to date [3]. Participants on tirzepatide 15mg lost an average of 22.5kg, with 91% achieving at least 5% weight loss and 57% achieving at least 20% weight loss. While no direct trial has compared Wegovy 2.4mg head-to-head with Mounjaro, indirect comparison of trial data suggests tirzepatide may produce greater average weight loss, though individual response varies significantly.

Understanding the Mechanism: Why Results Differ

The question of whether Wegovy is better than Mounjaro relates fundamentally to their different mechanisms. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve glycaemic control [4]. Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist, which activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously.

This dual agonism may explain tirzepatide's enhanced weight loss efficacy observed in trials. GIP receptor activation appears to complement GLP-1 effects by further reducing food intake, improving insulin sensitivity, and potentially increasing energy expenditure [4]. However, the dual mechanism also means different side effect profiles and individual response patterns, which we discuss throughout this comparison.

Is Wegovy Better Than Mounjaro for Side Effects and Tolerability?

When evaluating whether Wegovy is better than Mounjaro, tolerability is as important as efficacy for long-term treatment success. Both medications share a similar side effect profile dominated by gastrointestinal symptoms, as both work partly by slowing gastric emptying. In the STEP trials, the most common adverse events with Wegovy were nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. Most GI side effects were mild to moderate and decreased over time with continued treatment.

Mounjaro's side effect profile in SURMOUNT-1 showed similar patterns: nausea (31-38% across doses), diarrhoea (23-27%), constipation (16-19%), and vomiting (10-14%) [3]. Interestingly, despite higher weight loss efficacy, tirzepatide did not show proportionally higher rates of GI side effects compared to semaglutide in indirect comparison. Discontinuation rates due to adverse events were 4.3% with Wegovy in STEP 1 and 4.3-6.2% with tirzepatide in SURMOUNT-1, suggesting comparable overall tolerability.

Individual tolerability varies considerably, and neither medication is categorically better for side effects. Some patients tolerate semaglutide better, others tirzepatide. The gradual dose escalation protocol used with both treatments helps minimise side effects. At Cured Pharmacy, our prescribers assess individual risk factors, medical history, and previous GLP-1 experience to recommend the most suitable option. Both treatments require the same precautions regarding contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2.

Is Wegovy Better Than Mounjaro: UK Pricing and Value Comparison

Cost is a critical factor when determining whether Wegovy is better than Mounjaro for your circumstances. At Cured Pharmacy, Mounjaro is priced from £124.99 per four-week supply, with new patients receiving £20 off their first order using code Weightlossnew. Wegovy is priced from £124.99 per four-week supply, making it the more affordable option on a per-dose basis. These prices include the required online clinical consultation with a UK-registered prescriber, prescription, and discreet next-day delivery.

When comparing value, it's important to consider both upfront cost and expected efficacy. While Mounjaro costs more per month, clinical trial data suggests it may deliver greater average weight loss, potentially reaching treatment goals faster or achieving greater total weight reduction [3]. Wegovy offers a lower monthly cost with proven substantial efficacy, which may represent better value for patients on tighter budgets or those who respond well to GLP-1-only therapy.

Neither medication is currently funded by the NHS for routine weight management except in specialist weight management services meeting strict criteria, meaning most UK patients pay privately. At Cured Pharmacy, we guarantee the cheapest UK price for both treatments with transparent upfront pricing — you see the exact cost before completing your clinical assessment. We never add hidden consultation fees or membership charges, and our superintendent pharmacist Tarun Kumar ensures every patient receives the same competitive pricing and clinical standard of care.

Long-Term Cost Considerations

When asking is Wegovy better than Mounjaro from a financial perspective, consider the full treatment duration. Both medications are intended for long-term use — weight regain commonly occurs after discontinuation [1]. A typical treatment course spans 12-24 months or longer, meaning the monthly price difference compounds significantly over time. Patients should budget for sustained treatment and discuss realistic timelines with their prescriber during the initial consultation.

Is Wegovy Better Than Mounjaro for Specific Patient Groups?

The question of whether Wegovy is better than Mounjaro doesn't have a universal answer — suitability depends on individual patient characteristics. For patients with type 2 diabetes seeking both glycaemic control and weight loss, Mounjaro is licensed for diabetes management (Wegovy is not) and demonstrated superior HbA1c reduction in the SURPASS trials [2]. Tirzepatide reduced HbA1c by up to 2.5% in diabetic patients, compared to approximately 1.5% with semaglutide 1mg.

For patients without diabetes focused purely on weight loss, both medications are effective options. Those who have previously tried and tolerated Ozempic (semaglutide 1mg) may transition well to Wegovy, as it contains the same active ingredient at a higher dose. Conversely, patients who experienced limiting side effects or inadequate response with semaglutide may achieve better outcomes with tirzepatide's dual mechanism.

Age, BMI, and weight loss goals also influence the choice. In SURMOUNT-1, higher proportions of patients on tirzepatide 15mg achieved clinically significant weight loss thresholds: 91% lost ≥5%, 77% lost ≥10%, 57% lost ≥20%, and 40% lost ≥25% of body weight [3]. For patients with higher BMI or ambitious weight loss targets, Mounjaro's superior average efficacy may make it the preferred choice despite higher cost. Our clinical team at Cured Pharmacy conducts individualised assessments to match treatment to patient goals, medical history, and budget.

Is Wegovy Better Than Mounjaro: Dosing and Administration Comparison

When comparing whether Wegovy is better than Mounjaro, practical administration factors matter for long-term adherence. Both are once-weekly subcutaneous injections supplied in pre-filled pens. Wegovy follows a five-step dose escalation: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then maintenance dose of 2.4mg weekly [1]. This gradual escalation minimises gastrointestinal side effects.

Mounjaro uses a similar escalation strategy starting at 2.5mg weekly, increasing by 2.5mg increments every 4 weeks to reach maintenance doses of 5mg, 7.5mg, 10mg, 12.5mg, or 15mg depending on individual response and tolerability [3]. The flexibility of multiple maintenance dose options allows more precise titration to balance efficacy and side effects. Some patients achieve their goals at lower doses with fewer side effects, while others require the maximum dose for optimal results.

Both pens are designed for ease of use with hidden needles and simple push-button injection. Neither requires refrigeration after first use (though both should be stored refrigerated before opening). Injection site rotation is recommended with both treatments to minimise injection site reactions. From a practical standpoint, neither medication is categorically easier to use — the choice between Wegovy and Mounjaro should be based on clinical factors rather than administration convenience, as both offer comparable user-friendly delivery systems.

Missed Dose Protocols

Both medications have specific guidance for missed doses. If you miss a Wegovy dose and it's been less than 5 days, take it as soon as you remember. If more than 5 days have passed, skip that dose and resume your regular schedule. For Mounjaro, take the missed dose within 4 days; if more than 4 days have passed, skip it and continue with your next scheduled dose. Neither requires restarting the escalation schedule for a single missed dose, though prolonged interruptions may require prescriber guidance.

Is Wegovy Better Than Mounjaro: Making Your Decision at Cured Pharmacy

So, is Wegovy better than Mounjaro? The evidence suggests both are highly effective, MHRA-licensed treatments for chronic weight management, with tirzepatide (Mounjaro) demonstrating superior average weight loss in clinical trials but at a higher monthly cost, and semaglutide (Wegovy) offering proven substantial efficacy at a more affordable price point. Neither is universally superior — the optimal choice depends on your individual medical history, weight loss goals, budget, previous treatment experience, and tolerability profile.

At Cured Pharmacy, our UK-registered prescribers conduct comprehensive online consultations to assess your suitability for either treatment. The consultation takes under 3 minutes, and if clinically appropriate, your prescription is issued the same day with discreet next-day delivery. We stock both Wegovy and Mounjaro with guaranteed UK-licensed, genuine medication sourced through licensed wholesalers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure the highest standards of pharmaceutical care.

We offer the cheapest UK price for both treatments with transparent pricing: Wegovy from £124.99 and Mounjaro from £124.99, with £20 off your first order using code Weightlossnew. Unlike some providers, we show you the exact cost before you complete your consultation — no hidden fees, no membership charges, no surprises. Our clinical team is available on (+44) 116 4646009 to discuss which treatment may be most suitable for your circumstances. Whether you choose Wegovy or Mounjaro, you'll receive ongoing support, medication reminders, and access to our pharmacist team throughout your weight loss journey.

Starting Your Treatment Journey

To begin your assessment for Wegovy or Mounjaro, visit our weight loss collection and select your preferred treatment. Complete the short medical questionnaire honestly and thoroughly — this information allows our prescribers to make safe, appropriate clinical decisions. If you're unsure which treatment to choose, you can indicate this in your consultation, and our prescriber will recommend the most suitable option based on your individual circumstances. All consultations are reviewed by UK-registered prescribers, and you'll receive a clear outcome with next steps within hours of submission.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
4. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.